Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer Retraction in /10.3892/ijo.2022.5382

Dong,Huaying; Wang,Wei; Chen,Ru; Zhang,Yu; Zou,Kejian; Ye,Mulin; He,Xionghui; Zhang,Fan; Han,Jing

doi:10.3892/ijo.2018.4467

Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer

Retraction in: /10.3892/ijo.2022.5382

Authors:
- Huaying Dong
- Wei Wang
- Ru Chen
- Yu Zhang
- Kejian Zou
- Mulin Ye
- Xionghui He
- Fan Zhang
- Jing Han
View Affiliations

Affiliations: Department of General Surgery, Hainan General Hospital, Haikou, Hainan 570311, P.R. China
Published online on: July 3, 2018 https://doi.org/10.3892/ijo.2018.4467
Pages: 1013-1026
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Currently, resistance to trastuzumab, a human epidermal growth factor receptor 2 (HER2) inhibitor, has become an important obstacle to improving the clinical outcome of patients with advanced HER2+ breast cancer. While cell behavior may be modulated by long non‑coding RNAs (lncRNAs), the contributions of lncRNAs within extracellular vesicles (exosomes) are largely unknown. To this end, the involvement and regulatory functions of potential lncRNAs contained within exosomes during the formation of chemoresistance in human breast cancer were investigated. Trastuzumab-resistant cell lines were established by continuously grafting HER2+ SKBR-3 and BT474 cells into trastuzumab-containing culture medium. An lncRNA microarray assay followed by reverse transcription‑quantitative polymerase chain reaction analysis identified that lncRNA-small nucleolar RNA host gene 14 (SNHG14) was upregulated in trastuzumab-resistant cells when compared with parental breast cancer cells. Functional experimentation demonstrated that knockdown of lncRNA‑SNHG14 potently promoted trastuzumab-induced cytotoxicity. Furthermore, extracellular lncRNA‑SNHG14 was able to be incorporated into exosomes and transmitted to sensitive cells, thus disseminating trastuzumab resistance. Treatment of sensitive cells with exosomes highly expressing lncRNA‑SNHG14 induced trastuzumab resistance, while knockdown of lncRNA‑SNHG14 abrogated this effect. The Signal Transduction Reporter Array indicated that lncRNA‑SNHG14 may promote the effect of trastuzumab by targeting the apoptosis regulator Bcl‑2 (Bcl‑2)/apoptosis regulator BAX (Bax) signaling pathway. Furthermore, the expression level of serum exosomal lncRNA‑SNHG14 was upregulated in patients who exhibited resistance to trastuzumab, compared with patients exhibiting a response. Therefore, lncRNA‑SNHG14 may be a promising therapeutic target for patients with HER2+ breast cancer.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007. View Article : Google Scholar : PubMed/NCBI
3	Vu T and Claret FX: Trastuzumab: Updated mechanisms of action and resistance in breast cancer. Front Oncol. 2:622012. View Article : Google Scholar : PubMed/NCBI
4	Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, et al: Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial. Lancet Oncol. 14:1183–1192. 2013. View Article : Google Scholar : PubMed/NCBI
5	Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD and Maihle NJ: Trastuzumab-induced HER reprogramming in 'resistant' breast carcinoma cells. Cancer Res. 69:2191–2194. 2009. View Article : Google Scholar : PubMed/NCBI
6	Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al American Society of Clinical Oncology/College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 131:18–43. 2007.PubMed/NCBI
7	Donepudi MS, Kondapalli K, Amos SJ and Venkanteshan P: Breast cancer statistics and markers. J Cancer Res Ther. 10:506–511. 2014.PubMed/NCBI
8	ENCODE Project Consortium: An integrated encyclopedia of DNA elements in the human genome. Nature. 489:57–74. 2012. View Article : Google Scholar : PubMed/NCBI
9	Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, et al: Landscape of transcription in human cells. Nature. 489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zhang S, Qin C, Cao G, Xin W, Feng C and Zhang W: Systematic analysis of long non-coding RNAs in the senescence-accelerated mouse prone 8 brain using RNA sequencing. Mol Ther Nucleic Acids. 5:e3432016. View Article : Google Scholar
11	Brockdorff N: Non-coding RNA and Polycomb recruitment. RNA. 19:429–442. 2013. View Article : Google Scholar : PubMed/NCBI
12	Li P, Zhang X, Wang H, Wang L, Liu T, Du L, Yang Y and Wang C: MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemo-resistance through EZH2. Mol Cancer Ther. 16:739–751. 2017. View Article : Google Scholar : PubMed/NCBI
13	Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, Tempst P, Rosenfeld MG, Glass CK and Kurokawa R: Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature. 454:126–130. 2008. View Article : Google Scholar : PubMed/NCBI
14	Lee TH, D'Asti E, Magnus N, Al-Nedawi K, Meehan B and Rak J: Microvesicles as mediators of intercellular communication in cancer - the emerging science of cellular 'debris'. Semin Immunopathol. 33:455–467. 2011. View Article : Google Scholar : PubMed/NCBI
15	Théry C, Ostrowski M and Segura E: Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 9:581–593. 2009. View Article : Google Scholar : PubMed/NCBI
16	Pefanis E, Wang J, Rothschild G, Lim J, Kazadi D, Sun J, Federation A, Chao J, Elliott O, Liu ZP, et al: RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity. Cell. 161:774–789. 2015. View Article : Google Scholar : PubMed/NCBI
17	Kourembanas S: Exosomes: Vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol. 77:13–27. 2015. View Article : Google Scholar
18	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
19	Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
20	Shi SJ, Wang LJ, Yu B, Li YH, Jin Y and Bai XZ: LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 6:11652–11663. 2015. View Article : Google Scholar : PubMed/NCBI
21	Soo CY, Song Y, Zheng Y, Campbell EC, Riches AC, Gunn-Moore F and Powis SJ: Nanoparticle tracking analysis monitors microvesicle and exosome secretion from immune cells. Immunology. 136:192–197. 2012. View Article : Google Scholar : PubMed/NCBI
22	Xu SY, Huang X and Cheong KL: Recent advances in marine algae polysaccharides: Isolation, structure, and activities. Mar Drugs. 15:152017. View Article : Google Scholar
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
24	Baker SC, Bauer SR, Beyer RP, Brenton JD, Bromley B, Burrill J, Causton H, Conley MP, Elespuru R, Fero M, et al: The External RNA Controls Consortium: A progress report. Nat Methods. 2:731–734. 2005. View Article : Google Scholar : PubMed/NCBI
25	Schindelin J, Rueden CT, Hiner MC and Eliceiri KW: The ImageJ ecosystem: An open platform for biomedical image analysis. Mol Reprod Dev. 82:518–529. 2015. View Article : Google Scholar : PubMed/NCBI
26	Kogure T, Lin WL, Yan IK, Braconi C and Patel T: Intercellular nanovesicle-mediated microRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology. 54:1237–1248. 2011. View Article : Google Scholar : PubMed/NCBI
27	Xin H, Li Y, Buller B, Katakowski M, Zhang Y, Wang X, Shang X, Zhang ZG and Chopp M: Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 30:1556–1564. 2012. View Article : Google Scholar : PubMed/NCBI
28	Wang Z, Wang N, Li W, Liu P, Chen Q, Situ H, Zhong S, Guo L, Lin Y, Shen J, et al: Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway. Carcinogenesis. 35:2346–2356. 2014. View Article : Google Scholar : PubMed/NCBI
29	Yu D and Hung MC: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 19:6115–6121. 2000. View Article : Google Scholar
30	Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD and Feuer EJ; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 353:1784–1792. 2005. View Article : Google Scholar : PubMed/NCBI
31	Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ and Slamon DJ: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 15:537–547. 1997. View Article : Google Scholar : PubMed/NCBI
32	Parise C and Caggiano V: Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California. Cancer Epidemiol. 38:556–562. 2014. View Article : Google Scholar : PubMed/NCBI
33	Telli ML, Chang ET, Kurian AW, Keegan TH, McClure LA, Lichtensztajn D, Ford JM and Gomez SL: Asian ethnicity and breast cancer subtypes: A study from the California Cancer Registry. Breast Cancer Res Treat. 127:471–478. 2011. View Article : Google Scholar
34	Kurian AW, Fish K, Shema SJ and Clarke CA: Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res. 12:R992010. View Article : Google Scholar : PubMed/NCBI
35	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
36	Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W and Geuze HJ: Exosome: From internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci. 113:3365–3374. 2000.PubMed/NCBI
37	van den Boorn JG, Dassler J, Coch C, Schlee M and Hartmann G: Exosomes as nucleic acid nanocarriers. Adv Drug Deliv Rev. 65:331–335. 2013. View Article : Google Scholar
38	Kucharzewska P and Belting M: Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J Extracell Vesicles. 2:22013. View Article : Google Scholar
39	Mercer TR and Mattick JS: Structure and function of long non-coding RNAs in epigenetic regulation. Nat Struct Mol Biol. 20:300–307. 2013. View Article : Google Scholar : PubMed/NCBI
40	Yang H, Fu H, Xu W and Zhang X: Exosomal non-coding RNAs: A promising cancer biomarker. Clin Chem Lab Med. 54:1871–1879. 2016. View Article : Google Scholar : PubMed/NCBI
41	Li Q, Shao Y, Zhang X, Zheng T, Miao M, Qin L, Wang B, Ye G, Xiao B and Guo J: Plasma long non-coding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumour Biol. 36:2007–2012. 2015. View Article : Google Scholar
42	Sadikovic B, Fernandes P, Zhang VW, Ward PA, Miloslavskaya I, Rhead W, Rosenbaum R, Gin R, Roa B and Fang P: Mutation Update for UBE3A variants in Angelman syndrome. Hum Mutat. 35:1407–1417. 2014. View Article : Google Scholar : PubMed/NCBI
43	Liu G, Ye Z, Zhao X and Ji Z: SP1-induced up-regulation of lncRNA SNHG14 as a ceRNA promotes migration and invasion of clear cell renal cell carcinoma by regulating N-WASP. Am J Cancer Res. 7:2515–2525. 2017.
44	Zhang J, Fan D, Jian Z, Chen GG and Lai PB: Cancer specific long non-coding RNAs show differential expression patterns and competing endogenous RNA potential in hepatocellular carcinoma. PLoS One. 10:e01410422015. View Article : Google Scholar
45	Yue Y, Zhang J, Yang L, Liu S, Qi J, Cao Q, Zhou C, Wang Y, Kijlstra A, Yang P, et al: Association of long non-coding RNAs polymorphisms with ankylosing spondylitis, Vogt-Koyanagi-Harada disease, and Behcet's disease. Invest Ophthalmol Vis Sci. 59:1158–1166. 2018. View Article : Google Scholar : PubMed/NCBI
46	Tan Q, Yu Y, Li N, Jing W, Zhou H, Qiu S, Liang C, Yu M and Tu J: Identification of long non-coding RNA 00312 and 00673 in human NSCLC tissues. Mol Med Rep. 16:4721–4729. 2017. View Article : Google Scholar : PubMed/NCBI
47	Tan Q, Zuo J, Qiu S, Yu Y, Zhou H, Li N, Wang H, Liang C, Yu M and Tu J: Identification of circulating long non-coding RNA GAS5 as a potential biomarker for non-small cell lung cancer diagnosisnon-small cell lung cancer, long non-coding RNA, plasma, GAS5, biomarker. Int J Oncol. 50:1729–1738. 2017. View Article : Google Scholar : PubMed/NCBI
48	Kim KM, Abdelmohsen K, Mustapic M, Kapogiannis D and Gorospe M: RNA in extracellular vesicles. Wiley Interdiscip Rev RNA. 8:82017. View Article : Google Scholar
49	Boukouris S and Mathivanan S: Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin Appl. 9:358–367. 2015. View Article : Google Scholar : PubMed/NCBI
50	Keller S, Ridinger J, Rupp AK, Janssen JW and Altevogt P: Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med. 9:862011. View Article : Google Scholar : PubMed/NCBI
51	Barok M, Joensuu H and Isola J: Trastuzumab emtansine: Mechanisms of action and drug resistance. Breast Cancer Res. 16:2092014. View Article : Google Scholar : PubMed/NCBI